Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial

Julie Strizki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Carisa De Anda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Arthur Fridman(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jiejun Du(Merck & Co., Inc., Rahway, NJ, USA (United States)), Amanda Paschke(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michelle Brown(University Hospital of Zurich), Matthew G. Johnson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jay A. Grobler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Patricia Carmelitano(Merck & Co., Inc., Rahway, NJ, USA (United States))
Infectious Diseases and Therapy
April 25, 2024
10.1007/s40121-024-00947-w
Cited by 1

Related Papers

Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
|Science|2004|1.8k
Antibiotic Susceptibility Profiles of <i>Escherichia coli</i> Strains Lacking Multidrug Efflux Pump Genes
|Antimicrobial Agents and Chemotherapy|2001|502
Selective small-molecule inhibition of an RNA structural element
|Nature|2015|419
Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation
|Biochemical Journal|2006|272
Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag
|Journal of Virology|2005|265